Table 2.

Summary of included Pharmacoeconomic studies.

Study	Location	Research view	Economic model	Disease	Intervention measure		Economic research methods	Economic research indexes
					Comparison group	Control group
Lin WS 2004[25]	China	Not reported	Not used	Acute ischemic stroke	Cerebrolysin (Bi’aoxing, Lizhusaile) + conventional treatment	Citicoline + conventional treatment	Cost-Effectiveness Analysis	Incremental cost effectiveness ratio (△C/△E)
Zhang GX 2010[26]	China	Not reported	Not used	Cerebral infarction	Cerebrolysin+ conventional treatment	Acanthopanax senticosus injection + conventional treatment/Edaravone + conventional treatment	Cost-Effectiveness Analysis	Incremental cost effectiveness ratio (△C/△E)
Li G 2013[27]	China	Not reported	Not used	Acute cerebral infarction	Cerebrolysin+ conventional treatment	Gangliosides + conventional treatment	Cost-Effectiveness Analysis	Cost effectiveness ratio (C/E)
Men P 2016[28]	China	Not reported	Not used	Acute ischemic stroke	Cerebrolysin + conventional treatment	Conventional treatment	Cost-Effectiveness Analysis	Incremental cost effectiveness ratio (△C/△E)
He X 2017[29]	China	Not reported	Not used	Acute ischemic stroke	Cerebrolysin (Ninzhexin, Shuratai, and Qu’ao) + conventional treatment	Conventional treatment	Cost-Effectiveness Analysis	Incremental cost effectiveness ratio (△C/△E)
Strilciuc, S 2023[30]	Romanian	A payer perspective	Not used	Acute ischemic stroke	Cerebrolysin	Placebo	Cost-Effectiveness Analysis	Incremental cost effectiveness ratio (△C/△E)